Personalized Approach in the Treatment of Triple Negative Breast Cancer: Literature Review and Perspectives

Popov AY, Karmazanovsky GG, Ryabov KY, Andreenko EA, Simonov AD, Gritskevich AA, Makarov VA, Dmitrieva TA and Oluwatchegun OM

Department of Chemotherapy, "National Medical Research Center of Surgery named after. A.V. Vishnevsky" Ministry of Health of Russia, Russia
Academician of the Russian Academy of Sciences, Russia
Central Asian Medical University, Uzbekistan
NACPP Clinic, Moscow, Russia
"Russian University of Peoples' Friendship named after. Patric Lumumba", Moscow, Russia

^*Correspondance to: Popov Anatoly Yu 

 PDF  Full Text Review Article | Open Access

Abstract:

Triple Negative Breast Cancer (TNBC) refers to a tumor lacking estrogen and progesterone receptors expression and is classified as HER2 negative, while the proliferative activity index (Ki67) shows high values. Thus, TNBC is characterized by the lack of "standard receptors." Recent studies have shown the need for a more detailed classification related to TNBC due to a high variability within the subtypes. Limited therapy choices, aggressive form, and early recurrence are all current concerns. The search for new targeted drugs and points application are highly important in the development of therapy for TNBC.

Keywords:

Breast cancer; Triple negative subtype of tumor; Inherited mutations; Androgen receptors

Cite the Article:

Popov AY, Karmazanovsky GG, Ryabov KY, Andreenko EA, Simonov AD, Gritskevich AA, et al. Personalized Approach in the Treatment of Triple Negative Breast Cancer: Literature Review and Perspectives. Clin Oncol. 2024;9:2097..